Most patients begin semaglutide at 0.25 mg once weekly, then increase by 0.25 mg increments every 714 days
Prolonged insulin-induced hypoglycaemia reduces ss-cell activity rather than number in pancreatic islets in non-diabetic rats
Semaglutide and tirzepatide are both glucagon-like peptide-1 GLP-1 receptor agonists, which means that they work in the same way to reduce appetite and regulate blood sugar levels
Finally, individuals with a history of heart failure, ischaemic heart disease, unstable angina, myocardial infarction, aortic aneurysm or dissection, stroke (ischaemic or haemorrhagic stroke), cerebral infarction, transient ischaemic attack, carotid intervention or surgery, coronary stenting, percutaneous coronary intervention (PCI) or coronary artery bypass before inclusion to the cohort or prior to the index event were also excluded
Come for the culture shift, stay for the vision of wellness that isnt just digitalbut deeply human